Impact of TP53, KRAS, and APC Mutations on Neoadjuvant Chemotherapy Outcomes in Locally Advanced Rectal Cancer.

ABSTRACT: Despite recent advances in neoadjuvant strategies for locally advanced rectal cancer (LARC), optimal chemotherapy regimens and the role of genetic biomarkers in guiding treatment remain unclear. Moreover, predictive markers are urgently needed for radiation-sparing strategies. Therefore, we aimed to assess the predictive and prognostic value of TP53, KRAS, and APC mutations in patients with LARC undergoing neoadjuvant chemotherapy (NACT) by retrospectively analyzing 43 patients with LARC who underwent NACT without radiation. Treatment response was assessed using RECIST criteria, revealing that 55.8% of patients exhibited a complete or partial response, which was significantly correlated with improved recurrence-free survival (p = 0.015). Conversely, tumor regression grade (TRG) did not pre

SUBMITTER: Takeda T 

PROVIDER: S-EPMC12580864 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature